Cargando…

Immune Checkpoint Inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: Elective Affinities

Since endometrial cancers (ECs) are frequently TMB-H and MSI-H/dMMR tumors, this element has provided the rationale for testing immune checkpoint inhibitors (ICIs), which have recently emerged as a potential game-changer. However, several questions remain to be addressed, including the identificatio...

Descripción completa

Detalles Bibliográficos
Autor principal:	Rizzo, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267485/ https://www.ncbi.nlm.nih.gov/pubmed/35807197 http://dx.doi.org/10.3390/jcm11133912

Ejemplares similares

Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer
por: Antill, Yoland, et al.
Publicado: (2021)

Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status
por: Sawada, Kiyoka, et al.
Publicado: (2023)

Genomic Determinants of De Novo Resistance to Immune Checkpoint Blockade in Mismatch Repair–Deficient Endometrial Cancer
por: Gulhan, Doga C., et al.
Publicado: (2020)

Comparison of Methods for Testing Mismatch Repair Status in Endometrial Cancer
por: Mendiola, Marta, et al.
Publicado: (2023)

Role of Immune Checkpoint Inhibitors in Advanced or Recurrent Endometrial Cancer
por: Arora, Ena, et al.
Publicado: (2018)

Immune Checkpoint Inhibitor-related Endocrinopathies
por: Lu, Difei, et al.
Publicado: (2022)

Hallmarks of Resistance to Immune-Checkpoint Inhibitors
por: Karasarides, Maria, et al.
Publicado: (2022)

Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer
por: Hill, Breana L, et al.
Publicado: (2023)

POLE and Mismatch Repair Status, Checkpoint Proteins and Tumor-Infiltrating Lymphocytes in Combination, and Tumor Differentiation: Identify Endometrial Cancers for Immunotherapy
por: Dong, Dandan, et al.
Publicado: (2021)

Managing cardiotoxicity associated with immune checkpoint inhibitors
por: Upadhrasta, Sireesha, et al.
Publicado: (2019)

Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer?
por: Li, Yinuo, et al.
Publicado: (2023)

Expression of DNA mismatch repair proteins in melanoma patients treated with immune checkpoint inhibitors
por: Gambichler, T., et al.
Publicado: (2022)

DNA mismatch repair in cancer immunotherapy
por: Guan, Junhong, et al.
Publicado: (2023)

Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?
por: Huyghe, Nicolas, et al.
Publicado: (2019)

Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers
por: Amodio, Vito, et al.
Publicado: (2021)

Digging into phenotype change in mismatch repair deficient endometrial carcinoma and treatment with immune checkpoint inhibition, a case report
por: Rey-Cárdenas, Macarena, et al.
Publicado: (2023)

Role of Mismatch Repair Deficiency Status and Microsatellite Instability in Relation to the Expression of Immune Checkpoint Proteins in Colorectal Cancer
por: Sharma, Antariksha, et al.
Publicado: (2023)

Cancer and Immune Checkpoint Inhibitor Treatment in the Era of SARS-CoV-2 Infection
por: Gambichler, Thilo, et al.
Publicado: (2020)

Clinicopathologic features of endometrial cancer with mismatch repair deficiency
por: Gordhandas, Sushmita, et al.
Publicado: (2020)

Clinicopathological characteristics of endometrial carcinomas according to DNA mismatch repair protein status
por: de Freitas, Daniela, et al.
Publicado: (2023)

Somatic mutations in genes associated with mismatch repair predict survival in patients with metastatic cancer receiving immune checkpoint inhibitors
por: Liu, Yongping, et al.
Publicado: (2020)

IMMU-14. IMMUNE CHECKPOINT INHIBITOR THERAPY FOR TREATMENT OF SYNCHRONOUS CANCERS IN PAEDIATRIC PATIENTS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY
por: Henderson, Jacob, et al.
Publicado: (2020)

Relationship between DNA Mismatch Repair Deficiency and Endometrial Cancer
por: Masuda, Kenta, et al.
Publicado: (2011)

Advances in genetic technologies result in improved diagnosis of mismatch repair deficiency in colorectal and endometrial cancers
por: Evans, D Gareth, et al.
Publicado: (2022)

Comparison of Tissue Mismatch Repair Protein Deficiency between Early- and Advanced-Stage Endometrial Cancer
por: Chaowiwatkun, Kamonporn, et al.
Publicado: (2023)

Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer
por: Su, Alan, et al.
Publicado: (2023)

Immune checkpoint inhibitors win the 2018 Nobel Prize
por: Huang, Pei-Wei, et al.
Publicado: (2019)

Dearth of ICD Codes for Complications of Immune Checkpoint Inhibitors Impedes Clinical Care and Research
por: Cheung, Yee-Ming M, et al.
Publicado: (2023)

Expression of Programmed Cell Death Ligand-1 and Mismatch Repair Status in Endometrial Carcinomas
por: Rajendran, Madhubala, et al.
Publicado: (2023)

IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience?
por: Brandi, Giovanni, et al.
Publicado: (2022)

Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer
por: Loukovaara, Mikko, et al.
Publicado: (2021)

Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency
por: Cohen, Romain, et al.
Publicado: (2021)

Mismatch repair–deficient prostate cancer with parenchymal brain metastases treated with immune checkpoint blockade
por: Sena, Laura A., et al.
Publicado: (2021)

An Analysis of Clinical, Surgical, Pathological and Molecular Characteristics of Endometrial Cancer According to Mismatch Repair Status. A Multidisciplinary Approach
por: Dondi, Giulia, et al.
Publicado: (2020)

Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer
por: Yamashita, Hitomi, et al.
Publicado: (2017)

Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?
por: Musacchio, Lucia, et al.
Publicado: (2020)

Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab
por: Sahin, Ilyas, et al.
Publicado: (2021)

Investigation of the relationship between immune checkpoints and mismatch repair deficiency in recurrent and nonrecurrent glioblastoma
por: ÇAKIR, Emel, et al.
Publicado: (2021)

Immuno-Contexture and Immune Checkpoint Molecule Expression in Mismatch Repair Proficient Colorectal Carcinoma
por: Giacomelli, Mauro, et al.
Publicado: (2023)

Heterogenous mismatch-repair status in colorectal cancer
por: Joost, Patrick, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9qrb81oq50b4t1207dg1ev5v9v